Brodalumab, a human monoclonal antibody against IL-17RA, which mediates the downstream signaling of IL-17A, IL-17F, IL-17A/F, IL-17C, and IL-17E, has been approved for the treatment of psoriasis [161]. Here, IL17A is linked to psoriasis.